Evidence map›Paper›PMID 34315874›Full record

ArticleNature communications2021

GWAS of serum ALT and AST reveals an association of SLC30A10 Thr95Ile with hypermanganesemia symptoms.

Lucas D Ward, Ho-Chou Tu, Chelsea B Quenneville, Shira Tsour, Alexander O Flynn-Carroll, Margaret M Parker, Aimee M Deaton, Patrick A J Haslett, Luca A Lotta, Niek Verweij and 6 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 2 pooled it
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Excessive CabioRxiv : the preprint server for biology · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Lucas D WardAlnylam Pharmaceuticals, Cambridge, MA, USA. lward@alnylam.com.ORCID http://orcid.org/0000-0002-8017-809X
Ho-Chou TuAlnylam Pharmaceuticals, Cambridge, MA, USA.
Chelsea B QuennevilleAlnylam Pharmaceuticals, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-5488-058X
Shira TsourAlnylam Pharmaceuticals, Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-1382-4044
Alexander O Flynn-CarrollAlnylam Pharmaceuticals, Cambridge, MA, USA.
Margaret M ParkerAlnylam Pharmaceuticals, Cambridge, MA, USA.
Aimee M DeatonAlnylam Pharmaceuticals, Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-0365-3077
Patrick A J HaslettAlnylam Pharmaceuticals, Cambridge, MA, USA.
Luca A LottaRegeneron Genetics Center, Tarrytown, NY, USA.
Niek VerweijRegeneron Genetics Center, Tarrytown, NY, USA.
Manuel A R FerreiraRegeneron Genetics Center, Tarrytown, NY, USA.
Regeneron Genetics Center
Geisinger-Regeneron DiscovEHR Collaboration
Aris BarasRegeneron Genetics Center, Tarrytown, NY, USA.ORCID http://orcid.org/0000-0002-6830-3396
Gregory HinkleAlnylam Pharmaceuticals, Cambridge, MA, USA.
Paul NioiAlnylam Pharmaceuticals, Cambridge, MA, USA.
Regeneron (United States) · USGeisinger Health System · USAlnylam Pharmaceuticals (United States) · US

Funding

Medical Research Council MC_PC_17228Medical Research Council MC_QA137853
6 · The paper itself

Abstract

Understanding mechanisms of hepatocellular damage may lead to new treatments for liver disease, and genome-wide association studies (GWAS) of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) serum activities have proven useful for investigating liver biology. Here we report 100 loci associating with both enzymes, using GWAS across 411,048 subjects in the UK Biobank. The rare missense variant SLC30A10 Thr95Ile (rs188273166) associates with the largest elevation of both enzymes, and this association replicates in the DiscovEHR study. SLC30A10 excretes manganese from the liver to the bile duct, and rare homozygous loss of function causes the syndrome hypermanganesemia with dystonia-1 (HMNDYT1) which involves cirrhosis. Consistent with hematological symptoms of hypermanganesemia, SLC30A10 Thr95Ile carriers have increased hematocrit and risk of iron deficiency anemia. Carriers also have increased risk of extrahepatic bile duct cancer. These results suggest that genetic variation in SLC30A10 adversely affects more individuals than patients with diagnosed HMNDYT1.

Indexed as

Genome-Wide Association StudyAlanine TransaminaseAspartate AminotransferasesCation Transport ProteinsGene Expression RegulationGenetic LinkageGenetic LociGenome, HumanHeLa CellsHematocritHeterozygoteHomeostasisHumansLiverManganeseMolecular Sequence AnnotationAlanine TransaminaseAspartate AminotransferasesCation Transport ProteinsManganeseSLC30A10 protein, human

Identifiers

PMID34315874
PMCPMC8316433
OpenAlexW3027379059

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.